ICCC Immucell Corp.

ImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020

ImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020
EN
06/10/2020

Underlying

ICCCImmucell Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immucell Corp.

 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended...

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025 Conference Call Scheduled for Friday, November 14, 2025 at 9:00 AM ET PORTLAND, Maine, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2025 after the market closes on Thursday, Novembe...

November 6, 2025 1 EN
 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell Announces Onboarding of New CEO and Related Management Change...

ImmuCell Announces Onboarding of New CEO and Related Management Changes PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes. Effective November 1, 2025, Olivier te Boekhorst began serving as President and CEO of the Company, succeeding Michael F. Brigham. At its meeting o...

November 4, 2025 1 EN
 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025 PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2025. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close...

October 7, 2025 1 EN
 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell Announces Selection of its Next President and CEO

ImmuCell Announces Selection of its Next President and CEO PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has selected Olivier te Boekhorst as its next President and CEO. The Company anticipates a start date of November 1, 2025 for Mr. te Boekhorst. Mr. te Boekhorst is currently an Operating Partner at ARCHIMED, ...

September 29, 2025 1 EN
 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell Announces Unaudited Financial Results for the Quarter Ended J...

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025 PORTLAND, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2025. Product Sales Highlights: During the second quarter of 2025, product sales increased by 18% to approximately $6.4 million c...

August 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch